NEO-MEDROL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NEO-MEDROL (NEO-MEDROL).
Neo-Medrol is a combination of neomycin (an aminoglycoside antibiotic) and methylprednisolone (a corticosteroid). Neomycin inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, while methylprednisolone suppresses inflammation by binding to glucocorticoid receptors, modulating gene expression, and inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
| Metabolism | Methylprednisolone is primarily metabolized in the liver via CYP3A4. Neomycin is minimally absorbed through intact skin; systemic absorption is negligible. |
| Excretion | Renal (primarily as inactive metabolites); <5% unchanged. Biliary/fecal excretion minimal. |
| Half-life | Plasma terminal half-life: 2-4 hours (methylprednisolone); clinical effect half-life ~18-36 hours due to receptor occupancy. |
| Protein binding | ~78% bound to corticosteroid-binding globulin (CBG) and albumin. |
| Volume of Distribution | Approximately 0.8-1.2 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral: 70-90%; IM: 100% (systemic); Intra-articular or soft-tissue injection: predominantly local with partial systemic absorption (variable). |
| Onset of Action | IV: rapid, within 30 minutes; IM: 1-2 hours; Oral: 2-4 hours. |
| Duration of Action | Single dose: 12-36 hours depending on dose and route; prolonged suppression of HPA axis can persist for weeks with chronic use. |
| Molecular Weight | 416.5 |
Initial dose: 4-48 mg orally per day, divided into 1-4 doses, depending on severity. Intravenous or intramuscular: 10-500 mg/day as methylprednisolone sodium succinate, given as single or divided doses. Intra-articular or soft tissue injection: 4-80 mg as methylprednisolone acetate, depending on joint size.
| Dosage form | OINTMENT |
| Renal impairment | No dose adjustment required for renal impairment; methylprednisolone is primarily hepatically metabolized. However, monitor for fluid retention in severe renal impairment. |
| Liver impairment | Child-Pugh Class A: No adjustment. Child-Pugh Class B: Consider 50% dose reduction. Child-Pugh Class C: Use with caution; consider 50-75% dose reduction and monitor for adrenal suppression. |
| Pediatric use | Oral: 0.5-1.7 mg/kg/day or 5-25 mg/m²/day in divided doses every 6-12 hours. Intravenous: 0.5-1.7 mg/kg/day or 5-25 mg/m²/day as methylprednisolone sodium succinate. Intra-articular: 2-20 mg depending on joint size. |
| Geriatric use | Start at low end of dosing range due to increased risk of osteoporosis, glucose intolerance, and fluid retention. Titrate slowly and monitor for adverse effects. Adjust dose based on response and tolerance. |
| 1st trimester | Corticosteroids are generally avoided in the first trimester unless essential due to a small increased risk of oral clefts. Use only if clearly needed. |
| 2nd trimester | May cause fetal growth restriction and adrenal suppression. Use lowest effective dose for shortest duration. |
| 3rd trimester | May cause neonatal adrenal suppression if used near term. Use with caution, monitor neonate. |
Clinical note
Comprehensive clinical and safety monograph for NEO-MEDROL (NEO-MEDROL).
| Placental transfer | Methylprednisolone (active ingredient in Neo-Medrol) crosses the placenta; however, it is extensively metabolized to the less active 11-keto form, reducing fetal exposure. The placental transfer ratio is approximately 10-15% of maternal concentration. |
| Breastfeeding | Small amounts of corticosteroids enter breast milk; unlikely to cause adverse effects in infants at maternal doses up to 80 mg/day prednisone equivalent. Monitor infant for growth and adrenal suppression. |
■ FDA Black Box Warning
Topical corticosteroids should not be used in the treatment of diaper dermatitis. Prolonged use may lead to hypothalamic-pituitary-adrenal (HPA) axis suppression. Neomycin may cause ototoxicity when applied to open wounds or damaged skin.
| Serious Effects |
Systemic fungal infectionsKnown hypersensitivity to methylprednisolone or any component of the formulationAdministration of live or live-attenuated vaccines in immunosuppressive doses
| Precautions | Avoid prolonged use on large body surface areas or under occlusive dressings. Monitor for systemic corticosteroid effects, especially in children. Neomycin may cause allergic contact sensitization. Discontinue if irritation or infection develops. |
| Food/Dietary | No known food interactions. Avoid alcohol if systemic absorption is a concern (not typically significant with ophthalmic use). |
Loading safety data…
| Lactation Rating | L2 (Safer) |
| Teratogenic Risk | First trimester: Increased risk of cleft palate (odds ratio 3.35) and congenital heart defects. Second and third trimesters: Fetal growth restriction, adrenal suppression, and premature birth. Chronic use: Risk of neonatal adrenal insufficiency. |
| Fetal Monitoring | Maternal: Blood pressure, blood glucose, bone density if long-term. Fetal: Ultrasound for growth and anatomy, nonstress test in third trimester, neonatal adrenal function assessment. |
| Fertility Effects | May suppress ovulation and spermatogenesis at high doses; reversible upon dose reduction. No evidence of permanent fertility impairment. |
| Clinical Pearls | Neo-Medrol (neomycin sulfate and methylprednisolone acetate) is a combination ophthalmic suspension. Do not use for viral or fungal infections. Shake well before use. Avoid prolonged use due to risk of steroid-induced glaucoma and cataracts. Monitor intraocular pressure if used >10 days. Neomycin can cause contact dermatitis; discontinue if sensitivity develops. |
| Patient Advice | Shake the bottle vigorously before each use. · Do not touch the dropper tip to any surface to avoid contamination. · Remove contact lenses before application; wait at least 15 minutes before reinserting. · Use only for the prescribed duration; prolonged use may cause eye complications. · Report any eye pain, vision changes, or worsening redness immediately. · Do not use while wearing soft contact lenses due to preservative risk. |